Peeling Back The Layers: Exploring XOMA Through Analyst Insights
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on XOMA (NASDAQ:XOMA)…
Cracking The Code: Understanding Analyst Reviews For XOMA
4 analysts have expressed a variety of opinions on XOMA (NASDAQ:XOMA) over the past quarter, offering a diverse…
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Talphera Announces $26M Capital Commitment Through A Combination Of A Non-Dilutive Royalty Monetization And Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025$16 million of total equity committed with $6
XOMA Expands Its Commercial Royalty And Milestone Portfolio With DSUVIA Acquisition; Provided An $8M Non-Dilutive Royalty Capital Solution To Talphera
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of
